CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing selective inhibitors for the 20S proteasome to treat multiple myeloma and mantle cell lymphoma. By creating synthetic proteins that specifically target cancer cells, the aim is to reduce side effects associated with current therapies and advance peptide-based treatments in oncology.
Multiple myeloma (MM) is a cancer of plasma cells, that is incurable, and the second most common form of blood cancer.
Proteasome inhibitors (PIs) are considered a mainstay in the treatment of MM and mantle cell lymphoma (MCL).
Current drugs, based on PIs however, target the chymotrypsin-like activity of the 20S proteasome, and inhibit the activities of both the 20S and 26S proteasomes.
Thus, it is possible that selective drug intervention specifically inhibiting only the 20S proteasomes will re…
WEIZMANN INSTITUTE OF SCIENCE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
